Nonbiologic drugs in pediatric rheumatology

Anand Prahalad Rao; Nutan Kamath

doi:10.1007/978-981-10-1750-6_7

Nonbiologic drugs in pediatric rheumatology

Anand Prahalad Rao, Nutan Kamath

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The field of pediatric rheumatology has seen a decisive change in the way patients are being treated in last few decades. The diseases of this subspeciality be it JIA, SLE, vasculitis or JDM are chronic and require long term term treatment with drugs. The discovery of new drugs including BRMs and intelligent use of older drugs have made it possible to achieve remission in many of these conditions and provide patients with a better quality of life. This chapter highlights the pharmacology, intended uses and possible adverse side effects of many of these drugs. The information provided in this chapter should be a precursor for treating children with rheumatological illness.

Original language	English
Title of host publication	Pediatric Rheumatology
Subtitle of host publication	A Clinical Viewpoint
Publisher	Springer Science+Business Media Singapore Private Limited
Pages	55-75
Number of pages	21
ISBN (Electronic)	9789811017506
ISBN (Print)	9789811017490
DOIs	https://doi.org/10.1007/978-981-10-1750-6_7
Publication status	Published - 01-01-2016

All Science Journal Classification (ASJC) codes

Medicine(all)

Access to Document

10.1007/978-981-10-1750-6_7

Cite this

@inbook{1c21ad3afa8c4247ad7f35ecaf6d9d59,

title = "Nonbiologic drugs in pediatric rheumatology",

abstract = "The field of pediatric rheumatology has seen a decisive change in the way patients are being treated in last few decades. The diseases of this subspeciality be it JIA, SLE, vasculitis or JDM are chronic and require long term term treatment with drugs. The discovery of new drugs including BRMs and intelligent use of older drugs have made it possible to achieve remission in many of these conditions and provide patients with a better quality of life. This chapter highlights the pharmacology, intended uses and possible adverse side effects of many of these drugs. The information provided in this chapter should be a precursor for treating children with rheumatological illness.",

author = "Rao, {Anand Prahalad} and Nutan Kamath",

year = "2016",

month = jan,

day = "1",

doi = "10.1007/978-981-10-1750-6_7",

language = "English",

isbn = "9789811017490",

pages = "55--75",

booktitle = "Pediatric Rheumatology",

publisher = "Springer Science+Business Media Singapore Private Limited",

address = "Singapore",

}

TY - CHAP

T1 - Nonbiologic drugs in pediatric rheumatology

AU - Rao, Anand Prahalad

AU - Kamath, Nutan

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The field of pediatric rheumatology has seen a decisive change in the way patients are being treated in last few decades. The diseases of this subspeciality be it JIA, SLE, vasculitis or JDM are chronic and require long term term treatment with drugs. The discovery of new drugs including BRMs and intelligent use of older drugs have made it possible to achieve remission in many of these conditions and provide patients with a better quality of life. This chapter highlights the pharmacology, intended uses and possible adverse side effects of many of these drugs. The information provided in this chapter should be a precursor for treating children with rheumatological illness.

AB - The field of pediatric rheumatology has seen a decisive change in the way patients are being treated in last few decades. The diseases of this subspeciality be it JIA, SLE, vasculitis or JDM are chronic and require long term term treatment with drugs. The discovery of new drugs including BRMs and intelligent use of older drugs have made it possible to achieve remission in many of these conditions and provide patients with a better quality of life. This chapter highlights the pharmacology, intended uses and possible adverse side effects of many of these drugs. The information provided in this chapter should be a precursor for treating children with rheumatological illness.

UR - http://www.scopus.com/inward/record.url?scp=85018607696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018607696&partnerID=8YFLogxK

U2 - 10.1007/978-981-10-1750-6_7

DO - 10.1007/978-981-10-1750-6_7

M3 - Chapter

AN - SCOPUS:85018607696

SN - 9789811017490

SP - 55

EP - 75

BT - Pediatric Rheumatology

PB - Springer Science+Business Media Singapore Private Limited

ER -

Nonbiologic drugs in pediatric rheumatology

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this